PRKG1 and proteostasis deficiencies: Intriguingly, activation of PKG pharmacologically (PDE5 inhibitor, sildenafil) or genetically (expression of a constitutively active PKG) in a proteinopathy model (CryABR120G) reduced the accumulation of ubiquitinated proteins and cleared the degradation of misfolded, but not normal, proteins (Ranek et al., 2013).